Topical Steroid Selection for Dermatologic Conditions

Introduction to Topical Corticosteroid Use

The American Academy of Dermatology recommends selecting topical corticosteroid potency based on disease severity and anatomic location, using Class 1-2 for moderate-to-severe plaque psoriasis on the trunk and extremities, Class 3-5 for mild disease or maintenance therapy, and Class 6-7 exclusively for the face, genitals, and intertriginous areas 1, 2, 3

Topical corticosteroids are classified into 7 categories based on vasoconstriction potency, with Class 1 being ultra-high potency and Class 7 being low potency 1, 3
The classification system includes: Class 1 (ultra-high potency): Clobetasol propionate 0.05%, halobetasol propionate 0.05% 3, Class 2 (high potency): Betamethasone dipropionate 0.05%, fluocinonide 0.05%, amcinonide 0.1% 3, Class 3-5 (medium potency): Various formulations including triamcinolone acetonide 1, and Class 6-7 (low potency): Hydrocortisone 1-2.5% 3

For plaque psoriasis, use Class 1, 2, or 3-5 topical corticosteroids for up to 4 weeks as initial treatment, with Class 1 achieving 58-92% efficacy rates in moderate-to-severe disease 1, 3
For scalp psoriasis, any potency (Class 1-7) can be used for a minimum of 4 weeks for initial and maintenance treatment, with solutions preferred for scalp application 1, 4
For atopic dermatitis, start with medium-to-high potency (Class 3-4) for moderate-to-severe disease, then transition to low potency (Class 6-7) for maintenance, with potent topical corticosteroids demonstrating superior efficacy compared to mild agents (72% versus 47% improvement) 2, 3
For bullous pemphigoid, apply clobetasol propionate 0.05% cream or ointment 10-20 grams daily to lesional skin only for localized/mild disease, and 30-40 grams daily to entire body surface for extensive disease, with this approach being more effective and safer than systemic prednisone 1 mg/kg/day 5

Use only Class 6-7 (low potency) steroids in high-risk areas such as the face, genitals, and intertriginous regions due to increased absorption and atrophy risk, with face and intertriginous areas being at greatest risk for adverse effects including atrophy, striae, telangiectasia 1, 2, 3
For thick plaques on the trunk/extremities, use Class 1-2 (ultra-high to high potency) for initial treatment of chronic, thick lesions 1, 3

Apply once daily for potent topical corticosteroids, which is equally effective as twice daily application, with Class 1 steroids having a maximum 2-4 weeks continuous use and Class 2-5 steroids having up to 12 weeks under careful supervision 1, 3

Abnormal skin thinning occurs in only 1% of patients across trials, primarily with higher-potency steroids, with 16 cases with very potent, 6 with potent, 2 with moderate, 2 with mild steroids out of 2,266 participants 3
Other adverse effects include striae, folliculitis, telangiectasia, purpura, and rebound upon abrupt withdrawal, with gradual tapering after clinical improvement recommended to avoid rebound 1, 3

Combine topical corticosteroids with vitamin D analogues (calcipotriene) for psoriasis, alternate with topical calcineurin inhibitors (tacrolimus 0.1%, pimecrolimus) for facial/intertriginous areas or prolonged use >4 weeks, and add tazarotene with medium-to-high potency steroids for 8-16 weeks in psoriasis to reduce irritation and increase efficacy 1, 4, 6